<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Reprod Biol Endocrinol</journal-id><journal-title>Reproductive Biology and Endocrinology : RB&#x00026;E</journal-title><issn pub-type="epub">1477-7827</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1477-7827-7-116</article-id><article-id pub-id-type="pmid">19852793</article-id><article-id pub-id-type="doi">10.1186/1477-7827-7-116</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Prostaglandin treatment is associated with a withdrawal of progesterone and androgen at the receptor level in the uterine cervix</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Vladic-Stjernholm</surname><given-names>Ylva</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ylva.vladic-stjernholm@karolinska.se</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Vladic</surname><given-names>Tomislav</given-names></name><email>tomislav.vladic@telia.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Blesson</surname><given-names>Chellakkan S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>blesson.selvanesan@ki.se</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Ekman-Ordeberg</surname><given-names>Gunvor</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gunvor.ekman-ordeberg@ki.se</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Sahlin</surname><given-names>Lena</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>lena.sahlin@ki.se</email></contrib></contrib-group><aff id="I1"><label>1</label>Division for Obstetrics and Gynecology, Department of Women's and Children's Health, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden</aff><aff id="I2"><label>2</label>Division for Reproductive Endocrinology, Department of Women's and Children's Health, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>23</day><month>10</month><year>2009</year></pub-date><volume>7</volume><fpage>116</fpage><lpage>116</lpage><ext-link ext-link-type="uri" xlink:href="http://www.rbej.com/content/7/1/116"/><history><date date-type="received"><day>8</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>23</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Vladic-Stjernholm et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Vladic-Stjernholm et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Vladic-Stjernholm Ylva ylva.vladic-stjernholm@karolinska.se </dc:author><dc:title> Prostaglandin treatment is associated with a withdrawal of progesterone and androgen at the receptor level in the uterine cervix </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Reproductive Biology and Endocrinology 7(1): 116-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-7827(2009)7:1&#x0003c;116&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-7827</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Treatment with prostaglandin(PG)-E<sub>2 </sub>is clinically efficient for cervical priming. The aim of this study was to evaluate the impact of PG-E<sub>2 </sub>on the expression of the progesterone (PR), androgen (AR) and glucocorticoid (GR) receptors in human uterine cervix in prolonged pregnancy.</p><p>The study groups were postterm nulliparous women with unripe cervices undergoing cervical priming with PG-E<sub>2 </sub>before labor induction. Responders (n = 12) who delivered vaginally were compared with non-responders (n = 10), who underwent cesarean section due to failure to progress to the active phase of labor. Controls (n = 18) with vaginal partus at a normal gestational age served as a reference group. Cervical levels of PR-A and PR- B isoforms, AR and GR, serum levels of their ligands and sex hormone-binding globulin (SHBG) were quantified.</p><p>The responder group displayed lower total PR-AB and AR protein levels as compared to non-responders, and lower PR-B and AR protein levels as compared to controls. In addition, the PR mRNA level was lower in responders as compared to non-responders. The GR protein level did not differ between the groups.</p><p>We conclude that successful PG-E<sub>2 </sub>priming was followed by a progesterone and androgen withdrawal at the receptor level in the uterine cervix.</p></abstract></article-meta></front><body><sec><title>Background</title><p>In clinical practice, cases of maternal or fetal distress necessitate immediate induction of labor. Prostaglandins (PGs) from the E and F series are the main promoters of cervical ripening and myometrial contractility. The influence of PG-E<sub>2 </sub>in promotion of cervical maturation and uterine vasodilatation has been suggested as the primary functions of PGs in human parturition [<xref ref-type="bibr" rid="B1">1</xref>]. Local treatment with PG-E<sub>2 </sub>gel is efficient for cervical priming [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Prolonged pregnancy &#x02265; 42+0 gestational weeks occurs in 5-12% of pregnancies, predominantly in nulliparous women, exerting increased risks for perinatal mortality and morbidity [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Prolonged pregnancy is a key indication for cervical priming and induction of labor. The uterine cervix effaces towards the internal os and increases in diameter during the latency phase of labor, and it opens beyond 3-4 cm during the active phase. Late cervical ripening resembles an inflammatory reaction [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Progesterone, testosterone and cortisol are known to have anti-inflammatory properties [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Progesterone withdrawal associated with human parturition is characterized by decreased levels of the total progesterone receptor (PR) and an increased ratio of the inhibitory PR-A isoform to PR-B isoform form in the uterine cervix and myometrium [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>].</p><p>The aim of this study was to evaluate the impact of PG-E<sub>2 </sub>priming on the expression of the PR, androgen (AR) and glucocorticoid (GR) receptors in human uterine cervix in prolonged pregnancy. Serum levels of the receptor ligands, sex hormone-binding globulin (SHBG), and cervical expression of the prostaglandin synthase enzymes constitutive cyclooxygenase (COX)-1 and inducible COX-2 were also determined.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study patients</title><p>Ethics committee approval was obtained before the study (Karolinska University Hospital Ref No. 99-099). All women were healthy, non-smoking, had uncomplicated pregnancies, were without medication and gave informed consent to participate in the study. The study groups were nulliparous women with unripe cervices defined as a Bishop score &#x02264; 5 points. A Bishop score of &#x02265; 6 points was the criterion for a ripe cervix according to clinical guidelines [<xref ref-type="bibr" rid="B13">13</xref>]. The subjects were treated with PG-E<sub>2 </sub>in viscous gel (Minprostin<sup>&#x000ae; </sup>Pharmacia, Sweden) for cervical priming and labour induction in postterm pregnancy &#x02265; 42+0 gestational weeks (Table <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical data controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Age</bold></td><td align="left"><bold>Gest age</bold></td><td align="left"><bold>Oxytocin</bold></td><td align="left"><bold>Anaesthesia</bold></td><td align="left"><bold>Weight</bold></td><td align="left"><bold>Gender</bold></td></tr></thead><tbody><tr><td align="left">27</td><td align="left">37+5</td><td align="left">+</td><td align="left">EDA</td><td align="left">3190</td><td align="left">M</td></tr><tr><td align="left">37</td><td align="left">39+6</td><td align="left">+</td><td align="left">EDA</td><td align="left">3965</td><td align="left">M</td></tr><tr><td align="left">30</td><td align="left">39+4</td><td align="left">+</td><td align="left">EDA</td><td align="left">3280</td><td align="left">M</td></tr><tr><td align="left">34</td><td align="left">40+3</td><td align="left">+</td><td align="left">EDA</td><td align="left">3625</td><td align="left">M</td></tr><tr><td align="left">21</td><td align="left">37+0</td><td align="left">+</td><td align="left">EDA</td><td align="left">2595</td><td align="left">F</td></tr><tr><td align="left">29</td><td align="left">40+3</td><td align="left">+</td><td align="left">EDA</td><td align="left">3665</td><td align="left">F</td></tr><tr><td align="left">20</td><td align="left">40+5</td><td align="left">+</td><td align="left">EDA</td><td align="left">3815</td><td align="left">F</td></tr><tr><td align="left">23</td><td align="left">40+6</td><td align="left">+</td><td align="left">EDA</td><td align="left">3065</td><td align="left">M</td></tr><tr><td align="left">30</td><td align="left">39+3</td><td align="left">+</td><td align="left">EDA</td><td align="left">3130</td><td align="left">M</td></tr><tr><td align="left">32</td><td align="left">41+1</td><td align="left">+</td><td align="left">EDA</td><td align="left">3420</td><td align="left">M</td></tr><tr><td align="left">32</td><td align="left">40+5</td><td align="left">+</td><td align="left">N<sub>2</sub>O</td><td align="left">4175</td><td align="left">M</td></tr><tr><td align="left">28</td><td align="left">39+5</td><td align="left">+</td><td align="left">EDA</td><td align="left">3470</td><td align="left">M</td></tr><tr><td align="left">31</td><td align="left">40+1</td><td align="left">+</td><td align="left">EDA</td><td align="left">3590</td><td align="left">F</td></tr><tr><td align="left">26</td><td align="left">40+4</td><td align="left">+</td><td align="left">EDA</td><td align="left">3390</td><td align="left">F</td></tr><tr><td align="left">31</td><td align="left">40+1</td><td align="left">+</td><td align="left">N<sub>2</sub>O</td><td align="left">3540</td><td align="left">M</td></tr><tr><td align="left">27</td><td align="left">39+3</td><td align="left">+</td><td align="left">EDA</td><td align="left">2970</td><td align="left">M</td></tr><tr><td align="left">26</td><td align="left">41+0</td><td align="left">+</td><td align="left">EDA</td><td align="left">2815</td><td align="left">F</td></tr><tr><td align="left">36</td><td align="left">38+6</td><td align="left">+</td><td align="left">EDA</td><td align="left">4055</td><td align="left">M</td></tr><tr><td align="left">37</td><td align="left">40+5</td><td align="left">+</td><td align="left">EDA</td><td align="left">4130</td><td align="left">F</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>30</bold></td><td align="left"><bold>39+6</bold></td><td align="left"><bold>19/19</bold></td><td align="left"><bold>17/19</bold></td><td align="left"><bold>3470</bold></td><td align="left"><bold>F7/M12</bold></td></tr></tbody></table><table-wrap-foot><p>Oxytocin = infusion of oxytocin10 U/glucose 2,5% 500 mL for augmentation of labor. EDA = epidural anaesthesia, N<sub>2</sub>O = inhalation of nitrous oxide 50%/oxygen 50%.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Clinical data responders.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Age</bold></td><td align="left"><bold>Gest age</bold></td><td align="left"><bold>BS</bold></td><td align="left"><bold>PG-E</bold></td><td align="left"><bold>Oxytocin</bold></td><td align="left"><bold>Anaesthesia</bold></td><td align="left"><bold>Weight</bold></td><td align="left"><bold>Gender</bold></td></tr></thead><tbody><tr><td align="left">21</td><td align="left">42+5</td><td align="left">2</td><td align="left">4</td><td align="left">+</td><td align="left">EDA</td><td align="left">3410</td><td align="left">F</td></tr><tr><td align="left">31</td><td align="left">42+4</td><td align="left">2</td><td align="left">7</td><td align="left">+</td><td align="left">EDA</td><td align="left">4360</td><td align="left">M</td></tr><tr><td align="left">39</td><td align="left">42+2</td><td align="left">3</td><td align="left">0,5</td><td align="left">+</td><td align="left">EDA</td><td align="left">2870</td><td align="left">F</td></tr><tr><td align="left">28</td><td align="left">42+3</td><td align="left">4</td><td align="left">4</td><td align="left">+</td><td align="left">EDA</td><td align="left">3960</td><td align="left">F</td></tr><tr><td align="left">31</td><td align="left">42+2</td><td align="left">4</td><td align="left">2</td><td align="left">+</td><td align="left">EDA</td><td align="left">3815</td><td align="left">F</td></tr><tr><td align="left">37</td><td align="left">42+5</td><td align="left">0</td><td align="left">4</td><td align="left">+</td><td align="left">EDA</td><td align="left">3535</td><td align="left">F</td></tr><tr><td align="left">35</td><td align="left">42+5</td><td align="left">2</td><td align="left">2</td><td align="left">+</td><td align="left">EDA</td><td align="left">4010</td><td align="left">M</td></tr><tr><td align="left">21</td><td align="left">42+4</td><td align="left">4</td><td align="left">2</td><td align="left">+</td><td align="left">N<sub>2</sub>O, EDA</td><td align="left">3430</td><td align="left">M</td></tr><tr><td align="left">29</td><td align="left">42+3</td><td align="left">4</td><td align="left">4</td><td align="left">+</td><td align="left">N<sub>2</sub>O, EDA</td><td align="left">3625</td><td align="left">M</td></tr><tr><td align="left">28</td><td align="left">42+1</td><td align="left">2</td><td align="left">2</td><td align="left">+</td><td align="left">EDA</td><td align="left">4245</td><td align="left">M</td></tr><tr><td align="left">23</td><td align="left">42+4</td><td align="left">3</td><td align="left">2</td><td align="left">+</td><td align="left">EDA</td><td align="left">3540</td><td align="left">M</td></tr><tr><td align="left">30</td><td align="left">42+1</td><td align="left">4</td><td align="left">4</td><td align="left">+</td><td align="left">EDA</td><td align="left">3985</td><td align="left">M</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>30</bold></td><td align="left"><bold>42+4</bold></td><td align="left"><bold>3</bold></td><td align="left"><bold>3,1</bold></td><td align="left"><bold>12/12</bold></td><td align="left"><bold>12/12</bold></td><td align="left"><bold>3732</bold></td><td align="left"><bold>F5/M7</bold></td></tr></tbody></table><table-wrap-foot><p>BS = Bishop score (points) before priming, PG-E<sub>2 </sub>= accumulated PG-E<sub>2 </sub>dose (mg), Oxytocin = infusion of oxytocin10 U/glucose 2,5% 500 mL for induction of labor. EDA = epidural anaesthesia, N<sub>2</sub>O = inhalation of nitrous oxide 50%/oxygen 50%.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Clinical data non-responders.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Age</bold></td><td align="left"><bold>Gest age</bold></td><td align="left"><bold>BS</bold></td><td align="left"><bold>PG-E</bold></td><td align="left"><bold>Oxytocin</bold></td><td align="left"><bold>Anaesthesia</bold></td><td align="left"><bold>Weight</bold></td><td align="left"><bold>Gender</bold></td></tr></thead><tbody><tr><td align="left">32</td><td align="left">42+4</td><td align="left">2</td><td align="left">6</td><td align="left">-</td><td align="left">EDA</td><td align="left">3730</td><td align="left">F</td></tr><tr><td align="left">24</td><td align="left">42+3</td><td align="left">2</td><td align="left">2</td><td align="left">+</td><td align="left">EDA</td><td align="left">2830</td><td align="left">F</td></tr><tr><td align="left">31</td><td align="left">42+3</td><td align="left">2</td><td align="left">5</td><td align="left">+</td><td align="left">SPA</td><td align="left">3565</td><td align="left">F</td></tr><tr><td align="left">29</td><td align="left">42+6</td><td align="left">0</td><td align="left">5,5</td><td align="left">-</td><td align="left">SPA</td><td align="left">5130</td><td align="left">M</td></tr><tr><td align="left">26</td><td align="left">42+5</td><td align="left">0</td><td align="left">4</td><td align="left">-</td><td align="left">SPA</td><td align="left">3960</td><td align="left">F</td></tr><tr><td align="left">33</td><td align="left">42+4</td><td align="left">2</td><td align="left">6</td><td align="left">+</td><td align="left">SPA</td><td align="left">2905</td><td align="left">M</td></tr><tr><td align="left">29</td><td align="left">42+4</td><td align="left">2</td><td align="left">6</td><td align="left">+</td><td align="left">EDA</td><td align="left">3630</td><td align="left">F</td></tr><tr><td align="left">28</td><td align="left">42+5</td><td align="left">3</td><td align="left">6</td><td align="left">+</td><td align="left">EDA</td><td align="left">4180</td><td align="left">M</td></tr><tr><td align="left">37</td><td align="left">42+4</td><td align="left">3</td><td align="left">1</td><td align="left">+</td><td align="left">SPA</td><td align="left">5060</td><td align="left">M</td></tr><tr><td align="left">32</td><td align="left">42+6</td><td align="left">2</td><td align="left">6,5</td><td align="left">+</td><td align="left">SPA</td><td align="left">4930</td><td align="left">M</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>30</bold></td><td align="left"><bold>42+4</bold></td><td align="left">2</td><td align="left"><bold>4,7</bold></td><td align="left"><bold>7/10</bold></td><td align="left"><bold>10/10</bold></td><td align="left"><bold>3992</bold></td><td align="left"><bold>F5/M5</bold></td></tr></tbody></table><table-wrap-foot><p>BS = Bishop score (points) before priming, PG-E<sub>2 </sub>= accumulated PG-E<sub>2 </sub>dose (mg), Oxytocin = infusion of oxytocin10 U/glucose 2,5% 500 mL for induction of labor. EDA = epidural anaesthesia, SPA = spinal anaesthesia, N<sub>2</sub>O = inhalation of nitrous oxide 50%/oxygen 50%.</p></table-wrap-foot></table-wrap><p>Nulliparous women (n = 18) with spontaneous onset of labor and vaginal partus at a normal gestational length served as a reference control (C) group. They had a median age of 30 years (range 20-37) a median gestational age of 39+6 weeks (range 37+0-41+1). Oxytocin infusion (Syntocinon<sup>&#x000ae; </sup>10 U/glucose 2,5% 500 mL) for augmentation of labor was administered to all women according to the clinical guidelines [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>The responders (R) were nulliparous women (n = 12) who delivered vaginally after successful cervical priming with PG-E<sub>2</sub>. They had a median age of 30 years (range 21-39), a median gestational length of 42+4 weeks (range 42+1- 42+5) at partus, and median Bishop score of 3 points (range 0-4) at admission. All 12 women received oxytocin infusion for augmentation of labor.</p><p>The non-responders (NR) were nulliparous women (n = 10) who failed to enter the active phase of labor after treatment with PG-E<sub>2 </sub>and therefore delivered by cesarean section [<xref ref-type="bibr" rid="B15">15</xref>]. They had a median age of 30 years (range 24-37), a median gestational length of 42+4 weeks (range 42+1- 42+6) at partus, and a median Bishop score of 2 points (range 0-4) before PG-E<sub>2 </sub>treatment. Oxytocin infusion was administered to 7 of 10 women for induction of labor.</p><p>It was not possible to obtain a peripheral venous sample from every subject, due to practical reasons or lack of consent. The limited size of the cervical biopsies did not allow for analysis of both mRNA and immunohistochemistry (IHC) in all samples. Thus, the actual number for the mRNA analyses is given in the Results section.</p></sec><sec><title>Sampling procedure</title><p>The cervical biopsies were obtained transvaginally from the anterior part of the uterine cervix at the 12 o'clock position, from 10-20 mm depth within 30 min after delivery. The biopsies were divided and one half was immersion-fixed in 4% formaldehyde overnight, stored at 4&#x000b0;C in 70% ethanol and thereafter embedded in paraffin. The other half was immediately frozen at -70&#x000b0;C. Cervical tissue obtained from women after partus at a normal gestational length served as reference material.</p></sec><sec><title>Serum analyses</title><p>Peripheral venous samples were drawn immediately after parturition or at cesarean section. They were centrifuged at 3000 &#x000d7; G for 10 min and stored at -20 &#x000b0;C until analyzed.</p><p>Serum levels of progesterone and SHBG were determined by direct chemiluminiscence enzyme immunoassay using commercially available kits from Diagnostic Products Corp., Los Angeles, CA (Immulite<sup>&#x000ae;</sup>). Serum testosterone was determined by direct radioimmunoassay using a kit obtained from Diagnostic Products Corp. ("Coat-a-Count<sup>&#x000ae;</sup>"). Serum 5&#x003b1;-DHT was determined after destruction of cross reacting testosterone by oxidative cleavage of the 4-ene double bond with potassium permanganate followed by extraction, using a kit from Diagnostic Systems Laboratories Inc., Webster, Texas, U.S.A. Values obtained by this method were compared with those obtained by a method including extraction with diethyl ether, column chromatography on celite and subsequent radioimmunoassay and an excellent correlation was found [<xref ref-type="bibr" rid="B16">16</xref>]. Circulating progesterone binds in &#x0003c; 1%, testosterone in 70%, and its active metabolite 5&#x003b1;-dehydrotestosterone (DHT) in 28%, by high affinity to sex hormone-binding globulin (SHBG) [<xref ref-type="bibr" rid="B17">17</xref>]. The free androgen index (FAI) (total T/SHBG &#x000d7; 100) was calculated since the non SHBG-bound fraction is the biologically active fraction of steroid hormones [<xref ref-type="bibr" rid="B18">18</xref>].</p></sec><sec><title>RNA preparation and reverse transcription</title><p>Total RNA from frozen cervical tissue samples was purified with the RNeasy<sup>&#x000ae; </sup>kit (Qiagen GmbH, Hilden, Germany) according to a procedure for RNA isolation from fibrous tissues, including a DNase step, as recommended by the manufacturer. Two &#x003bc;g of total RNA from each sample was reverse transcribed at 37&#x000b0;C for 60 min in a final volume of 30 &#x003bc;l with a reaction mixture (Qiagen) containing 1 &#x000d7; RT buffer, dNTP mix (0.5 mM each dNTP), 600 ng random primers (Invitrogen, Paisley, UK), 10 units RNase inhibitor (Superase-In, Ambion, Austin, TX), and 4 U of Omniscript&#x02122; reverse transcriptase (Qiagen).</p></sec><sec><title>Real time PCR analysis</title><p>The oligonucleotide primers for PR-AB, PR-B, AR and Cyclophilin A are presented in Table <xref ref-type="table" rid="T4">4</xref>, as well as their predicted sizes. Real time PCR was performed in a DNA Engine Opticon&#x02122; 2 System (MJ Research, Waltham, MA). For PCR, the cDNAs corresponding to 40-100 ng (see Table <xref ref-type="table" rid="T2">2</xref>) RNA were added to 10 &#x003bc;l of Quantitect&#x02122; SYBR<sup>&#x000ae; </sup>Green PCR mix (Qiagen) containing HotStarTaq DNA polymerase, PCR buffer, dNTP mixture and 0.3 &#x003bc;M of each oligonucleotide primer in a final volume of 20 &#x003bc;l. The reactions were performed in opaque white 0.2 ml low-profile strip tubes sealed with optical flat caps (TLS-0851, TCS-0803, MJ Research). After initial incubation for 15 min at 95&#x000b0;C, the samples were subjected to 40-44 cycles of 10 s at 94&#x000b0;C, 15-20 s at 56&#x000b0;C (see Table <xref ref-type="table" rid="T4">4</xref>) and 20 s at 72&#x000b0;C with a final extension step at 72&#x000b0;C for 5 min. All PCR assays were performed twice. The purity of PCR products was confirmed by a melting curve analysis in all experiments (data not shown). All primers were designed to span an intron/exon boundary or to flank an intron. Thus, amplification of contaminating DNA was eliminated. Each PCR assay included a negative control containing a RNA sample without reverse transcription. The primers were based on the sequences of the human genes. The primer pairs (Table <xref ref-type="table" rid="T4">4</xref>) were designed with Primer3 software [<xref ref-type="bibr" rid="B19">19</xref>].</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Oligonucleotide primers used for real-time PCR.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>Accession No</bold></td><td align="left"><bold>Primers</bold><break/><bold>F = forward; R = reverse</bold></td><td align="left"><bold>Position</bold></td><td align="left"><bold>cDNA</bold></td><td align="left"><bold>Annealing step</bold></td></tr></thead><tbody><tr><td align="left">PRAB</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_000926.4">NM_000926.4</ext-link><break/>[<xref ref-type="bibr" rid="B37">37</xref>]</td><td align="left">F: tggaagaaatgactgcatcg<break/>R: agcatccagtgctctcacaa</td><td align="left">bp 2555-2574<break/>bp 2702-2683<break/>product: 148 bp</td><td align="left">40 ng</td><td align="left">56&#x000b0;C/15 s</td></tr><tr><td align="left">PRB</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_000926.4">NM_000926.4</ext-link><break/>[<xref ref-type="bibr" rid="B37">37</xref>]</td><td align="left">F: gactgagctgaaggcaaagg<break/>R: cgaaacttcaggcaaggtgtc</td><td align="left">bp 746-765<break/>bp 890-870<break/>product: 145 bp</td><td align="left">40 ng</td><td align="left">56&#x000b0;C/15 s</td></tr><tr><td align="left">AR</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_000044.2">NM_000044.2</ext-link></td><td align="left">F: taccagctcaccaagctcct<break/>R: gcttcactgggtgtggaaat</td><td align="left">bp 3687-3706<break/>bp 3882-3861<break/>product: 195 bp</td><td align="left">100 ng</td><td align="left">56&#x000b0;C/20 s</td></tr><tr><td align="left">Cyclophilin A</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_021130.3">NM_021130.3</ext-link></td><td align="left">F: gtggtgtttggcaaagtgaa<break/>R: tcgagttgtccacagtcagc</td><td align="left">bp 462-481<break/>bp 577-558<break/>product: 116 bp</td><td align="left">40 ng</td><td align="left">56&#x000b0;C/20 s</td></tr></tbody></table></table-wrap></sec><sec><title>Quantification of mRNA</title><p>To standardize the quantification method, cyclophilin A was selected as the housekeeping gene. The PCR amplification rate and the cycle threshold (Ct) values were analyzed using Opticon Monitor 3.0 software (MJ Research). The values of relative expression of genes of interest were normalized against the cyclophilin A product.</p></sec><sec><title>Immunohistochemical analysis</title><p>Immunostaining for the determination of PR-AB, PR-A, PR-B, AR, GR, COX-1 and COX-2 utilizing the avidin-biotin peroxidase complex (ABC) procedure was performed [<xref ref-type="bibr" rid="B20">20</xref>]. The 5 &#x003bc;m paraffin sections prepared from cervical biopsies were first dewaxed in Bioclear (Bio-Optica, Milan, Italy), rehydrated and washed with phosphate-buffered saline (PBS; pH 7.4). Thereafter the sections were subjected to microwave antigen retrieval in 0.01 M sodium citrate buffer (pH 6.0) for 10 min and then allowed to cool for 20 min. Subsequently, endogenous peroxidase activity was quenched by immersion in 3% hydrogen peroxide (Merck) in methanol for 10 min at room temperature (RT); followed by blocking non-specific binding of the primary antibody by incubation as shown in Table <xref ref-type="table" rid="T5">5</xref>, at RT. The sections were then incubated with the primary antibodies (see Table <xref ref-type="table" rid="T5">5</xref>). For the negative controls the primary antibody was replaced by mouse IgG (or in the case of GR rabbit IgG, and for COX-1 and -2 goat IgG) at a corresponding concentration to the antibody it replaced.</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Antibodies used in the study.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Protein</bold></td><td align="left"><bold>Primary ab, company and order number</bold></td><td align="left"><bold>Type and dilution</bold></td><td align="left"><bold>Inc temp + time</bold></td><td align="left"><bold>Blocking</bold></td><td align="left"><bold>Biotinylated 2 nd Ab all diluted 1:200</bold></td><td align="left"><bold>Buffer</bold></td><td align="left"><bold>Inc time in RT</bold></td></tr></thead><tbody><tr><td align="left">PRAB</td><td align="left">Zymed Lab Inc, 18-0172</td><td align="left">Mc mouse anti human 1:150</td><td align="left">RT 60 min</td><td align="left">1.5% NHS</td><td align="left">horse anti-mouse</td><td align="left">1.5% NHS in PBS</td><td align="left">45 min</td></tr><tr><td align="left">PRA</td><td align="left">Novocastra Labs Ltd, NCL-PGR312</td><td align="left">Mc mouse anti human 1:500</td><td align="left">RT 60 min</td><td align="left">1.5% NHS</td><td align="left">horse anti-mouse</td><td align="left">1.5% NHS in PBS</td><td align="left">45 min</td></tr><tr><td align="left">PRB</td><td align="left">Affinity BioReagents Inc, MA1-411</td><td align="left">Mc mouse Anti chick 1:100</td><td align="left">RT 60 min</td><td align="left">1.5% NHS</td><td align="left">horse anti-mouse</td><td align="left">1.5% NHS in PBS</td><td align="left">45 min</td></tr><tr><td align="left">AR</td><td align="left">DakoCyto-mation Inc, M3562</td><td align="left">Mc mouse anti human 1:100</td><td align="left">+4&#x000b0;C o/n</td><td align="left">2% NHS</td><td align="left">horse anti-mouse</td><td align="left">2% NHS in PBS</td><td align="left">30 min</td></tr><tr><td align="left">GR</td><td align="left">Affinity Bio Reagents Inc, PA1-511A</td><td align="left">Pc rabbit anti human 1:1000</td><td align="left">+4&#x000b0;C o/n</td><td align="left">2% NGS</td><td align="left">goat anti rabbit</td><td align="left">2% NGS in PBS</td><td align="left">60 min</td></tr><tr><td align="left">COX-1</td><td align="left">Santa Cruz Biotechnology Inc, sc 1752</td><td align="left">Pc goat anti human 1:100</td><td align="left">+37&#x000b0;C 60 min</td><td align="left">10% NRS</td><td align="left">rabbit anti goat</td><td align="left">10% NRS in PBS</td><td align="left">30 min</td></tr><tr><td align="left">COX-2</td><td align="left">Santa Cruz Biotechnology Inc, sc 1745</td><td align="left">Pc goat anti human 1:100</td><td align="left">+37&#x000b0;C 60 min</td><td align="left">10% NRS</td><td align="left">rabbit anti goat</td><td align="left">10% NRS in PBS</td><td align="left">30 min</td></tr></tbody></table><table-wrap-foot><p>Mc = monoclonal, Pc = polyclonal</p><p>RT = room temperature</p><p>biotinylated horse anti-mouse (Vector, Cat# BA-2000)</p><p>biotinylated goat anti rabbit (Vector, Cat# BA-1000)</p><p>biotinylated rabbit anti goat (Vector, Cat# BA-5000)</p></table-wrap-foot></table-wrap><p>The secondary biotinylated antibodies were incubated as shown in Table <xref ref-type="table" rid="T5">5</xref>, followed by incubation with an avidin-biotin horseradish peroxidase complex (Vectastain Elite, Cat# PK-6100) for 30 min at RT. The site of the bound enzyme was visualized by the application of 3,3'-diaminobenzidine (DAB kit, Vector, CA), a chromogen which produces a brown, insoluble precipitate when incubated with enzyme. The sections were counterstained with haematoxylin and dehydrated before they were mounted with Pertex (Histolab, Gothenburg).</p></sec><sec><title>Image analysis</title><p>A Leica microscope and Sony video camera (Park Ridge, NJ, U.S.A.) connected to a computer with an image analysis system (Leica Imaging System Ltd, Cambridge, UK) was used to assess quantitative values from immunohistochemistry. The quantification of immunostaining was performed as described previously [<xref ref-type="bibr" rid="B20">20</xref>]. In short, by using colour discrimination software the total area of positively stained nuclei was measured, and expressed as a ratio of the total area of cell nuclei.</p></sec><sec><title>Manual scoring</title><p>Two observers blinded to the identity of the slides performed all the assessments. The staining was evaluated semi-quantitatively using a grading system. The staining intensity was graded on a scale of (0) no staining, (1) faint, (2) moderate or (3) strong staining.</p></sec><sec><title>Statistical analyses</title><p>Clinical data were calculated with ANOVA/ANCOVA and significances were evaluated with Scheffe's test. Statistical calculation for serum hormone levels, receptor and mRNA levels was performed by ANOVA on ranks (Kruskal-Wallis test) and significances were evaluated by Dunn's test. Values with different letter designations are significantly different at level p &#x0003c; 0.05.</p></sec></sec><sec><title>Results</title><sec><title>Clinical data</title><p>The median maternal age and fetal gender did not differ between the groups. The neonatal weights were, as was expected, significantly higher in the postterm NR and R groups as compared to term C group (p &#x0003c; 0.05).</p></sec><sec><title>Serum levels of steroid hormones and SHBG</title><p>No differences were observed for progesterone, total testosterone, 5&#x003b1;-DHT levels or FAI between C (n = 16), R (n = 8) and NR (n = 8) groups. Serum progesterone (medians and range) was 299 (175-563) nmol/L in C, 220 (115-394) in R, and 234 (159-423) in NR. Serum testosterone was 3.06 (1.07-7.84) nmol/L in C, 3.42 (1.72-4.47) in R, and 2.93 (2.13-7.81) in NR. Serum 5&#x003b1;-DHT was 1.02 (0.04-2.42) nmol/L in C, 0.96 (0.57-1.18) in R, and 0.77 (0.58-1.22) in NR. Serum SHBG was significantly lower 301 (248-424) nmol/L in NR (n = 7), as compared to C 512 (304-708) and R 504 (236-644), whereas the FAI (T/SHBG &#x000d7; 100) was comparable between the groups 0.556 (0.187-2.56) in C, 0.770 (0.352-1.75) in R, and 0.834 (0.634-2.60) in NR.</p></sec><sec><title>mRNA levels</title><p>The PR-AB mRNA level was lower in responders as compared to the non-responders. The ratio between PR-AB and PR-B represents the PR-A mRNA level which did not change between the groups (Figure <xref ref-type="fig" rid="F1">1</xref>, upper middle panel). The PRB mRNA showed similar results as the PR-AB mRNA, but differences between groups did not reach significance. The AR mRNA level showed a tendency to be increased in the NR group, but did not reach significance (Figure <xref ref-type="fig" rid="F1">1</xref>, bottom panel).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Real-time PCR results for expression of PR-AB (upper), PR-AB/PR-B (upper middle), PR-B (lower middle) and AR (bottom) mRNAs in human cervix from the C (n = 11), R (n = 10) and NR (n = 4) groups respectively</bold>. The values of relative expression of target genes were normalized against cyclophilin A and displayed in arbitrary units. The ratio of PR-AB/PR-B represents the PR-A expression. The "box-and-whisker plot" represents the median value with 50% of all data falling within the box. The whiskers extend to the 5th and 95th percentiles. Boxes with different letter designations are significantly different, p &#x0003c; 0.05.</p></caption><graphic xlink:href="1477-7827-7-116-1"/></fig></sec><sec><title>Immunohistochemistry</title><p>The immunohistochemistry (IHC) scores for nuclear PR-AB (top panel), PR-A (upper middle panel), PR-B (lower middle panel) and AR (bottom panel) protein are presented in Figure <xref ref-type="fig" rid="F2">2</xref> and representative images of the IHC results are shown in Figure <xref ref-type="fig" rid="F3">3</xref>.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Immunostaining results for PR-AB (top), PR-A (upper middle), PR-B (lower middle) and AR (bottom) in stroma, as assessed by image analysis in cervical samples from controls (C), responders (R) and non-responders (NR)</bold>. The "box-and-whisker plot" represents the median value with 50% of all data falling within the box. The whiskers extend to the 5th and 95th percentiles. Boxes with different letter designations are significantly different, p &#x0003c; 0.05.</p></caption><graphic xlink:href="1477-7827-7-116-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Representative images of the immunostaining results for PR-AB (A-C), PR-A (D-F), PR-B (G-I), AR (J-L), COX-1 (M), COX-2 (N) and GR (O)</bold>. A negative control is shown for monoclonal antibodies (<bold>P</bold>) where the primary antibody was replaced by an equal amount of mouse IgG. The magnification bars represent 30 &#x003bc;m in all images.</p></caption><graphic xlink:href="1477-7827-7-116-3"/></fig><p>The IHC score for PR-AB was lower in responders as compared to non-responders (Figure <xref ref-type="fig" rid="F2">2</xref> top panel; Figure <xref ref-type="fig" rid="F3">3A-C</xref>). The IHC score for PR-B was lower in responders as compared to controls (Figure <xref ref-type="fig" rid="F2">2</xref> lower middle panel; Figure <xref ref-type="fig" rid="F3">3G-I</xref>). The IHC score for PR-A did not differ between study groups.</p><p>Immunohistochemical analysis revealed a significantly lower AR expression in the responders as compared to non-responders and controls (Figure <xref ref-type="fig" rid="F2">2</xref> bottom panel; Figure <xref ref-type="fig" rid="F3">3J-L</xref>).</p><p>The IHC scores for stromal COX-1, COX-2 and GR did not differ between groups (data not shown). Representative images from immunostaining of COX-1 (M), COX-2 (N) and GR (O) are shown in Figure <xref ref-type="fig" rid="F3">3</xref> as well as a negative control (P) where the primary antibody was replaced by an equal amount of mouse IgG.</p></sec></sec><sec><title>Discussion</title><p>Prolonged pregnancy constitutes a key indication for cervical priming and induction of labor [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Local treatment with PG-E<sub>2 </sub>gel has been shown to promote degradation of the extracellular matrix by increasing matrix metalloproteinase (MMP)-1 collagenase activity and by altering the proteoglycan content [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. Prostaglandin-E<sub>2 </sub>was reported to induce a functional progesterone withdrawal <italic>in vitro </italic>by increasing the inhibitory PR-A over PR-B expression through the protein kinase (PK)-C pathway in a human myometrial cell line (PHM1-31) [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>We found that serum levels of the receptor ligands were unchanged between the groups. However, the responder group displayed a lower cervical level of total PR-AB protein as compared to non-responders, and a lower cervical PR-B isoform level as compared to controls. The PR mRNA level was lower in responders as compared to non-responders, whereas no difference was found for the inhibitory PR-A isoform, which acts as a repressor of the PR-B isoform and other steroid receptors such as AR and GR [<xref ref-type="bibr" rid="B24">24</xref>]. Thus, decreased PR-AB and PR-B protein levels in responders indicate that PG-E<sub>2 </sub>priming leading to vaginal partus was associated with a nuclear PR withdrawal. The decreased PR-AB level in responders as compared to non-responders could be the consequence of a vaginal delivery. Nevertheless, the decreased PR-B level in responders as compared to controls cannot be explained by a different mode of delivery. Furthermore, PG-E<sub>2 </sub>promotes chemotaxis in neutrophils and macrophages, which enhances leukocyte extravasation into tissues by a synergistic action with chemotactic interleukin (IL)-8 [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. This is in accordance with the high leukocyte density and immunostaining for IL-8 observed in responders [<xref ref-type="bibr" rid="B27">27</xref>]. Pro-inflammatory cytokines activate the key pro-inflammatory transcription factor nuclear factor (NF)-&#x003ba;B, which was shown to exert a mutual negative interaction with PR [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. The comparable levels of COX-2 between the groups could be explained by the oxytocin treatment, since oxytocin initiates COX-2 gene transcription [<xref ref-type="bibr" rid="B29">29</xref>]. In addition, mechanical stretch induces COX-2 activity [<xref ref-type="bibr" rid="B30">30</xref>].</p><p>Since the cervical AR protein level was lower in responders not only as compared to non-responders who delivered by cesarean sections, but also as compared to controls who delivered spontaneously, the result cannot be explained by a different mode of delivery. The low AR protein level in responders indicates that successful PG-E<sub>2 </sub>priming was followed by an androgen withdrawal at the receptor level. This finding is in accordance with results from <italic>in vitro </italic>studies, in which androgens were reported to attenuate the synthesis of pro-inflammatory cytokines, inhibit MMP-1 production and regulate cervical resistance by altering the proteoglycan content [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B34">34</xref>]. Possible responses to the androgen withdrawal reported here could therefore be events leading to degradation of the extracellular matrix and cervical maturation [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B32">32</xref>].</p><p>Comparing the results of mRNA and protein for PR-AB, PR-A, PR-B and AR, all showed a similar expression pattern, although only PR-AB displayed significant changes for both mRNA and protein. The lack of significance for mRNA levels of PR-B and AR could be due to the fact that mRNA levels were detected in cervix tissue homogenate whereas the protein levels were determined in stromal nuclei.</p><p>The total GR protein level in human uterine cervical stroma and squamous epithelium was decreased after term labor as compared to late pregnancy [<xref ref-type="bibr" rid="B35">35</xref>], but no differences were found between the groups in the present study.</p><p>In conclusion, successful local PG-E<sub>2 </sub>treatment for cervical priming after prolonged pregnancy was correlated to a progesterone and androgen withdrawal at the receptor level. A comparable progesterone and androgen withdrawal was neither observed in the non-responders, who failed to enter the active phase of labor and underwent cesarean sections, nor in the term control group with spontaneous deliveries. The progesterone withdrawal is in accordance with the previous study [<xref ref-type="bibr" rid="B36">36</xref>], whereas the possibility of an androgen withdrawal, to our knowledge, has not been reported previously. We conclude that successful PG-E<sub>2 </sub>priming was followed by a functional progesterone and androgen withdrawal at the receptor level in the uterine cervix. It is possible that treatment with an antiprogestin or an antiandrogen could serve as a supplement to PG-E<sub>2 </sub>priming in non-responders.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>YVS and GEO conceived and designed the study. YVS collected all samples. GEO run the serum samples. TV did the statistics for the clinical data and hormone levels. CSB and LS performed and analysed all mRNA and immunohistochemistry analyses/data, including statistical evaluation. YVS and TV drafted the manuscript. LS and CSB helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We are grateful for skilful technical assistance from Britt Masironi and Yvonne Pierre. This work was supported by The Swedish Research Council (projects 73X-20137 (LS) 73X-14612 (GE)), The Swedish Society of Medicine (LS) and Karolinska Institutet. C.S. Blesson post doc position is financed by a grant from the Swedish Institute. Financial support was also provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hertelendy</surname><given-names>F</given-names></name><name><surname>Zakar</surname><given-names>T</given-names></name></person-group><article-title>Prostaglandins and the myometrium and cervix</article-title><source>Prostagl, Leukot Essen Fatty Acids</source><year>2004</year><volume>70</volume><fpage>207</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.plefa.2003.04.009</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ekman</surname><given-names>G</given-names></name><name><surname>Uldbjerg</surname><given-names>N</given-names></name><name><surname>Malmstrom</surname><given-names>A</given-names></name><name><surname>Ulmsten</surname><given-names>U</given-names></name></person-group><article-title>Increased postpartum collagenolytic activity in cervical connective tissue from women treated with prostaglandin E2</article-title><source>Gynecol Obstet Invest</source><year>1983</year><volume>16</volume><fpage>292</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">6315547</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindstr&#x000f6;m</surname><given-names>K</given-names></name><name><surname>Fernell</surname><given-names>E</given-names></name><name><surname>Westgren</surname><given-names>M</given-names></name></person-group><article-title>Developmental data in preschool children born after prolonged pregnancy</article-title><source>Acta Paediatrica</source><year>2005</year><volume>94</volume><fpage>1192</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">16278984</pub-id></citation></ref><ref id="B4"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Crowley</surname><given-names>P</given-names></name></person-group><article-title>Interventions for preventing or improving the outcome of delivery at or beyond term</article-title><source>Cochrane Database of Systematic Reviews</source><year>2000</year><fpage>CD000170</fpage></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>WHO: recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended October 14, 1976</article-title><source>Acta Obstet Gynecol Scand</source><year>1977</year><volume>56</volume><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">560099</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sennstrom</surname><given-names>MB</given-names></name><name><surname>Ekman</surname><given-names>G</given-names></name><name><surname>Westergren-Thorsson</surname><given-names>G</given-names></name><name><surname>Malmstrom</surname><given-names>A</given-names></name><name><surname>Bystrom</surname><given-names>B</given-names></name><name><surname>Endresen</surname><given-names>U</given-names></name><name><surname>Mlambo</surname><given-names>N</given-names></name><name><surname>Norman</surname><given-names>M</given-names></name><name><surname>Stabi</surname><given-names>B</given-names></name><name><surname>Brauner</surname><given-names>A</given-names></name></person-group><article-title>Human cervical ripening, an inflammatory process mediated by cytokines</article-title><source>Mol Hum Reprod</source><year>2000</year><volume>6</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">10729321</pub-id><pub-id pub-id-type="doi">10.1093/molehr/6.4.375</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stygar</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Vladic</surname><given-names>YS</given-names></name><name><surname>Ekman</surname><given-names>G</given-names></name><name><surname>Eriksson</surname><given-names>H</given-names></name><name><surname>Sahlin</surname><given-names>L</given-names></name></person-group><article-title>Increased level of matrix metalloproteinases 2 and 9 in the ripening process of the human cervix</article-title><source>Biol Reprod</source><year>2002</year><volume>67</volume><fpage>889</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">12193399</pub-id><pub-id pub-id-type="doi">10.1095/biolreprod.102.005116</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almawi</surname><given-names>WY</given-names></name><name><surname>Melemedjian</surname><given-names>OK</given-names></name></person-group><article-title>Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor</article-title><source>J Leuk Biol</source><year>2002</year><volume>71</volume><fpage>9</fpage><lpage>15</lpage></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stites</surname><given-names>DP</given-names></name><name><surname>Siiteri</surname><given-names>PK</given-names></name></person-group><article-title>Steroids as immunosuppressants in pregnancy</article-title><source>Immunol Rev</source><year>1983</year><volume>75</volume><fpage>117</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">6226589</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-065X.1983.tb01093.x</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stjernholm-Vladic</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Stygar</surname><given-names>D</given-names></name><name><surname>Ekman</surname><given-names>G</given-names></name><name><surname>Sahlin</surname><given-names>L</given-names></name></person-group><article-title>Differential regulation of the progesterone receptor A and B in the human uterine cervix at parturition</article-title><source>Gynecol Endocrin</source><year>2004</year><volume>18</volume><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1080/09513590310001651777</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stjernholm</surname><given-names>Y</given-names></name><name><surname>Sahlin</surname><given-names>L</given-names></name><name><surname>Malmstrom</surname><given-names>A</given-names></name><name><surname>Barchan</surname><given-names>K</given-names></name><name><surname>Eriksson</surname><given-names>HA</given-names></name><name><surname>Ekman</surname><given-names>G</given-names></name></person-group><article-title>Potential roles for gonadal steroids and insulin-like growth factor I during final cervical ripening</article-title><source>Obstet Gynecol</source><year>1997</year><volume>90</volume><fpage>375</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">9277647</pub-id><pub-id pub-id-type="doi">10.1016/S0029-7844(97)00245-7</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Mesiano</surname><given-names>S</given-names></name><name><surname>McGrath</surname><given-names>S</given-names></name></person-group><article-title>Hormone trajectories leading to human birth</article-title><source>Regul Pept</source><year>2002</year><volume>108</volume><fpage>159</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">12220740</pub-id><pub-id pub-id-type="doi">10.1016/S0167-0115(02)00105-2</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bishop</surname><given-names>EH</given-names></name></person-group><article-title>Pelvic Scoring for Elective Induction</article-title><source>Obstet Gynecol</source><year>1964</year><volume>24</volume><fpage>266</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">14199536</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Driscoll</surname><given-names>K</given-names></name><name><surname>Foley</surname><given-names>M</given-names></name><name><surname>MacDonald</surname><given-names>D</given-names></name></person-group><article-title>Active management of labor as an alternative to cesarean section for dystocia</article-title><source>Obstet Gynecol</source><year>1984</year><volume>63</volume><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">6700893</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>WJ</given-names></name><name><surname>Stevens</surname><given-names>D</given-names></name><name><surname>Welter</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>D</given-names></name></person-group><article-title>Factors predicting successful labor induction</article-title><source>Obstet Gynecol</source><year>1996</year><volume>88</volume><fpage>990</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">8942840</pub-id><pub-id pub-id-type="doi">10.1016/S0029-7844(96)00321-3</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>O</given-names></name><name><surname>Norming</surname><given-names>U</given-names></name><name><surname>Gustafsson</surname><given-names>S</given-names></name><name><surname>Eneroth</surname><given-names>P</given-names></name><name><surname>Astrom</surname><given-names>G</given-names></name><name><surname>Nyman</surname><given-names>CR</given-names></name></person-group><article-title>Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population</article-title><source>Br J Urol</source><year>1996</year><volume>77</volume><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">8814852</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mendel</surname><given-names>CM</given-names></name></person-group><article-title>The free hormone hypothesis: a physiologically based mathematical model</article-title><source>Endocr Rev</source><year>1989</year><volume>10</volume><fpage>232</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">2673754</pub-id><pub-id pub-id-type="doi">10.1210/edrv-10-3-232</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pardridge</surname><given-names>WM</given-names></name></person-group><article-title>Serum bioavailability of sex steroid hormones</article-title><source>Clin Endocrin Metab</source><year>1986</year><volume>15</volume><fpage>259</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/S0300-595X(86)80024-X</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rozen</surname><given-names>S</given-names></name><name><surname>Skaletsky</surname><given-names>H</given-names></name></person-group><article-title>Primer3 on the WWW for general users and for biologist programmers</article-title><year>2000</year><volume>132</volume><pub-id pub-id-type="pmid">10547847</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Masironi</surname><given-names>B</given-names></name><name><surname>Eriksson</surname><given-names>H</given-names></name><name><surname>Sahlin</surname><given-names>L</given-names></name></person-group><article-title>A comparative study of estrogen receptors alpha and beta in the rat uterus</article-title><source>Biol Reprod</source><year>1999</year><volume>61</volume><fpage>955</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">10491630</pub-id><pub-id pub-id-type="doi">10.1095/biolreprod61.4.955</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Granstr&#x000f6;m</surname><given-names>L</given-names></name><name><surname>Ekman</surname><given-names>G</given-names></name><name><surname>Malmstrom</surname><given-names>A</given-names></name></person-group><article-title>Insufficient remodelling of the uterine connective tissue in women with protracted labour</article-title><source>Br J Obst Gyn</source><year>1991</year><volume>98</volume><fpage>1212</fpage><lpage>1216</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>M</given-names></name><name><surname>Ekman</surname><given-names>G</given-names></name><name><surname>Malmstrom</surname><given-names>A</given-names></name></person-group><article-title>Prostaglandin E2-induced ripening of the human cervix involves changes in proteoglycan metabolism</article-title><source>Obstet Gynecol</source><year>1993</year><volume>82</volume><fpage>1013</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">8233252</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>G</given-names></name><name><surname>Zakar</surname><given-names>T</given-names></name><name><surname>Ku</surname><given-names>CY</given-names></name><name><surname>Sanborn</surname><given-names>BM</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Mesiano</surname><given-names>S</given-names></name></person-group><article-title>Prostaglandins differentially modulate progesterone receptor-A and -B expression in human myometrial cells: evidence for prostaglandin-induced functional progesterone withdrawal</article-title><source>J Clin Endocrin Metab</source><year>2004</year><volume>89</volume><fpage>1010</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-031037</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vegeto</surname><given-names>E</given-names></name><name><surname>Shahbaz</surname><given-names>MM</given-names></name><name><surname>Wen</surname><given-names>DX</given-names></name><name><surname>Goldman</surname><given-names>ME</given-names></name><name><surname>O'Malley</surname><given-names>BW</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function</article-title><source>Mol Endocrin</source><year>1993</year><volume>7</volume><fpage>1244</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1210/me.7.10.1244</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>WL</given-names></name><name><surname>Narumiya</surname><given-names>S</given-names></name></person-group><article-title>International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes</article-title><source>Pharmacol Rev</source><year>1994</year><volume>46</volume><fpage>205</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">7938166</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denison</surname><given-names>FC</given-names></name><name><surname>Calder</surname><given-names>AA</given-names></name><name><surname>Kelly</surname><given-names>RW</given-names></name></person-group><article-title>The action of prostaglandin E2 on the human cervix: stimulation of interleukin 8 and inhibition of secretory leukocyte protease inhibitor</article-title><source>Am J Obstet Gynecol</source><year>1999</year><volume>180</volume><fpage>614</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">10076137</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9378(99)70263-2</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sahlin</surname><given-names>L</given-names></name><name><surname>Stjernholm-Vladic</surname><given-names>Y</given-names></name><name><surname>Roos</surname><given-names>N</given-names></name><name><surname>Masironi</surname><given-names>B</given-names></name><name><surname>Ekman-Ordeberg</surname><given-names>G</given-names></name></person-group><article-title>Impaired leukocyte influx in cervix of postterm women not responding to prostaglandin priming</article-title><source>Reprod Biol Endocrin</source><year>2008</year><volume>6</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/1477-7827-6-36</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalkhoven</surname><given-names>E</given-names></name><name><surname>Wissink</surname><given-names>S</given-names></name><name><surname>Saag</surname><given-names>PT van der</given-names></name><name><surname>Burg</surname><given-names>B van der</given-names></name></person-group><article-title>Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor</article-title><source>JBC</source><year>1996</year><volume>271</volume><fpage>6217</fpage><lpage>6224</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.11.6217</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molnar</surname><given-names>M</given-names></name><name><surname>Rigo</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Romero</surname><given-names>R</given-names></name><name><surname>Hertelendy</surname><given-names>F</given-names></name></person-group><article-title>Oxytocin activates mitogen-activated protein kinase and up-regulates cyclooxygenase-2 and prostaglandin production in human myometrial cells</article-title><source>Am J Obstet Gynecol</source><year>1999</year><volume>181</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">10411794</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9378(99)70434-5</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leguizamon</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Younis</surname><given-names>H</given-names></name><name><surname>Nelson</surname><given-names>DM</given-names></name><name><surname>Sadovsky</surname><given-names>Y</given-names></name></person-group><article-title>Enhancement of amniotic cyclooxygenase type 2 activity in women with preterm delivery associated with twins or polyhydramnios</article-title><source>Am J Obstet Gynecol</source><year>2001</year><volume>184</volume><fpage>117</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">11174490</pub-id><pub-id pub-id-type="doi">10.1067/mob.2001.108076</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gornstein</surname><given-names>RA</given-names></name><name><surname>Lapp</surname><given-names>CA</given-names></name><name><surname>Bustos-Valdes</surname><given-names>SM</given-names></name><name><surname>Zamorano</surname><given-names>P</given-names></name></person-group><article-title>Androgens modulate interleukin-6 production by gingival fibroblasts in vitro</article-title><source>J Periodont</source><year>1999</year><volume>70</volume><fpage>604</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">10397515</pub-id><pub-id pub-id-type="doi">10.1902/jop.1999.70.6.604</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Dailey</surname><given-names>TL</given-names></name><name><surname>Long</surname><given-names>V</given-names></name><name><surname>Chien</surname><given-names>EK</given-names></name></person-group><article-title>Androgen-regulated cervical ripening: a structural, biomechanical, and molecular analysis</article-title><source>Am J Obstet Gynecol</source><year>2008</year><volume>198</volume><fpage>e541</fpage><lpage>549</lpage></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Agostino</surname><given-names>P</given-names></name><name><surname>Milano</surname><given-names>S</given-names></name><name><surname>Barbera</surname><given-names>C</given-names></name><name><surname>Di Bella</surname><given-names>G</given-names></name><name><surname>La Rosa</surname><given-names>M</given-names></name><name><surname>Ferlazzo</surname><given-names>V</given-names></name><name><surname>Farruggio</surname><given-names>R</given-names></name><name><surname>Miceli</surname><given-names>DM</given-names></name><name><surname>Miele</surname><given-names>M</given-names></name><name><surname>Castagnetta</surname><given-names>L</given-names></name><name><surname>Cillari</surname><given-names>E</given-names></name></person-group><article-title>Sex hormones modulate inflammatory mediators produced by macrophages</article-title><source>Ann NY Acad Sci</source><year>1999</year><volume>876</volume><fpage>426</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">10415638</pub-id><pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb07667.x</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Aso</surname><given-names>T</given-names></name></person-group><article-title>Testosterone inhibits matrix metalloproteinase-1 production in human endometrial stromal cells in vitro</article-title><source>Reproduction</source><year>2007</year><volume>133</volume><fpage>1233</fpage><lpage>1239</lpage><pub-id pub-id-type="pmid">17636177</pub-id><pub-id pub-id-type="doi">10.1530/rep.1.01089</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stjernholm-Vladic</surname><given-names>Y</given-names></name><name><surname>Stygar</surname><given-names>D</given-names></name><name><surname>Mansson</surname><given-names>C</given-names></name><name><surname>Masironi</surname><given-names>B</given-names></name><name><surname>Akerberg</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ekman-Ordeberg</surname><given-names>G</given-names></name><name><surname>Sahlin</surname><given-names>L</given-names></name></person-group><article-title>Factors involved in the inflammatory events of cervical ripening in humans</article-title><source>Reprod Biol Endocrinol</source><year>2004</year><volume>2</volume><fpage>74</fpage><pub-id pub-id-type="pmid">15500686</pub-id><pub-id pub-id-type="doi">10.1186/1477-7827-2-74</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stjernholm</surname><given-names>YM</given-names></name><name><surname>Sahlin</surname><given-names>L</given-names></name><name><surname>Eriksson</surname><given-names>HA</given-names></name><name><surname>Bystrom</surname><given-names>BE</given-names></name><name><surname>Stenlund</surname><given-names>PM</given-names></name><name><surname>Ekman</surname><given-names>GE</given-names></name></person-group><article-title>Cervical ripening after treatment with prostaglandin E2 or antiprogestin (RU486). Possible mechanisms in relation to gonadal steroids</article-title><source>Eur J Obstet Gynecol RB</source><year>1999</year><volume>84</volume><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/S0301-2115(98)00329-7</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastner</surname><given-names>P</given-names></name><name><surname>Krust</surname><given-names>A</given-names></name><name><surname>Turcotte</surname><given-names>B</given-names></name><name><surname>Stropp</surname><given-names>U</given-names></name><name><surname>Tora</surname><given-names>L</given-names></name><name><surname>Gronemeyer</surname><given-names>H</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><article-title>Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B</article-title><source>EMBO J</source><year>1990</year><volume>9</volume><fpage>1603</fpage><lpage>1614</lpage><pub-id pub-id-type="pmid">2328727</pub-id></citation></ref></ref-list></back></article> 